Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ICPT

Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug

Intercept Pharmaceuticals said Friday it will restructure itself after the FDA rejected its liver disease treatment. ICPT stock sank.

Investors Business Daily

Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug

Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug

The FDA will likely reject Intercept Pharmaceuticals' highly watched liver disease treatment, analysts said Monday as ICPT stock crashed.

Investors Business Daily

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years

Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

Investors Business Daily

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday.

Investors Business Daily

Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again

Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling). The update follows a recent request from the FDA that topline data from the REGENERATE reanalysis be provided to the agency for review before the meeting. SVB Leerink…

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

inkl

Read news from The Economist, FT, and more,
with one subscription

Intercept Pharmaceuticals: Q1 Earnings Insights

Intercept Pharmaceuticals: Q1 Earnings Insights

Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Outlook For Intercept Pharmaceuticals

Earnings Outlook For Intercept Pharmaceuticals

Intercept Pharmaceuticals (NASDAQ:ICPT) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Intercept Pharmaceuticals will report an earnings per share (EPS) of $-0.90.

Why Intercept Shares Are Rising Today

Why Intercept Shares Are Rising Today

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has

Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug

Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug

Intercept sold the international rights to its liver-disease treatment, Ocaliva, for up to $450 million on Thursday, and ICPT stock soared.

Investors Business Daily

Analyst Ratings For Intercept Pharmaceuticals

Analyst Ratings For Intercept Pharmaceuticals

Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

RBC Capital Markets

Intercept Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

261,570 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play